Potential of Optimal Preloading in Anti-CD20 Antibody Radioimmunotherapy: An Investigation Based on Pharmacokinetic Modeling
- 1 June 2010
- journal article
- research article
- Published by Mary Ann Liebert Inc in Cancer Biotherapy & Radiopharmaceuticals
- Vol. 25 (3), 279-287
- https://doi.org/10.1089/cbr.2009.0746
Abstract
Recently, it has been suggested that the concept of preloading is limited by using a standard amount of unlabeled antibody. To identify the potential of optimal preloading, a pharmacokinetic model that describes the biodistribution of anti-CD20 antibody was developed. Simulations were conducted for different tumor burdens, spleen sizes, and tumor permeabilities. The optimal amount of unlabeled antibody was determined for each scenario. These simulations show that the currently administered standard amount is not optimal. A preload of 150 mg or lower would result in equal or higher tumor uptake in all cases. For tumors with high permeability, the uptake of labeled antibody could be increased by a factor of 8.5 using the considerably reduced optimal preload. The most sensitive parameter for the choice of the optimal amount of unlabeled antibody is the tumor uptake index. The results indicate that a personalized approach for radioimmunotherapy (RIT) with anti-CD20 antibody is required to account for the interpatient variability. The optimal amount of unlabeled antibody, which has to be determined by using a pharmacokinetic model, could substantially improve tumor uptake and thus RIT with anti-CD20 antibody.Keywords
This publication has 26 references indexed in Scilit:
- Radioimmunotherapy with Anti-CD66 Antibody: Improving the Biodistribution Using a Physiologically Based Pharmacokinetic ModelJournal of Nuclear Medicine, 2010
- A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapyBlood, 2009
- Pretargeted Versus Directly Targeted Radioimmunotherapy Combined with Anti-CD20 Antibody Consolidation Therapy of Non-Hodgkin LymphomaJournal of Nuclear Medicine, 2009
- Improving Anti-CD45 Antibody Radioimmunotherapy Using a Physiologically Based Pharmacokinetic ModelJournal of Nuclear Medicine, 2009
- Update:Molecular Radiotherapy: Survey and Current StatusCancer Biotherapy & Radiopharmaceuticals, 2008
- Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's LymphomaNew England Journal of Medicine, 2008
- Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 AbBlood, 2008
- A Predictive Model of Therapeutic Monoclonal Antibody Dynamics and Regulation by the Neonatal Fc Receptor (FcRn)Annals of Biomedical Engineering, 2005
- Monoclonal antibody uptake in B-cell lymphomas: Experimental studies in nude mouse xenograftsCancer Immunology, Immunotherapy, 1993
- The effect of temperature on the binding kinetics and equilibrium constants of monoclonal antibodies to cell surface antigensMolecular Immunology, 1990